OP0005 Neoadjuvant chemotherapy plus chemoradiation (NACT-CCRT) versus chemoradiation plus adjuvant chemotherapy (CCRT-ACT) for locally advanced nasopharyngeal cancer: 3-Year results from a randomised trial

Chakrabandhu, Somvilai; Chitapanarux, Imjai; Onchan, Wimrak; Klunklin, Pitchayaponne; Supawongwattana, B.; Tharavichitkul, E.; Lorvidhaya, V.

doi:10.1016/j.ejca.2015.06.009

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another trial was excluded post-checking (94 patients) because follow-up was inferior to two years and no deaths were recorded. 18 Therefore, seven new trials (2,274 patients) were included. All of them had CRT as control arm, six studied the addition of IC before CRT and one the addition of AC after CRT.…”

Section: Description Of the Trials And Patientsmentioning

confidence: 99%

Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients

Blanchard

Lee

Carmel

et al. 2022

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Section: Description Of the Trials And Patientsmentioning

confidence: 99%

Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients

Blanchard

Lee

Carmel

et al. 2022

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Lee

Chan

et al. 2023

The Lancet Oncology

View full text Add to dashboard Cite

Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?

Cheng

Luo³

et al. 2018

Medicine

View full text Add to dashboard Cite

Background:The clinical application has widespread disagreement on the different regimens of neoadjuvant chemotherapy (NCT) in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC). We conducted a network meta-analysis (NMA) to evaluate the efficacy of the different NCT regimens in the treatment of NPC.Methods:A systematic literature search was performed using PubMed, Embase, and Cochran Library. Totally, 31 randomized controlled trials (RCTs) (n = 4062) met study selection criteria and were incorporated in this NMA study.Results:Our study showed that certain NCT regimens improved the prognosis of patients, and found out the relative best solution for each endpoint, such as paclitaxel, carboplatin, and gemcitabine for 1-year overall survival (OS) rate, cisplatin, calcium folinate, and 5-fluorouracil for 2-year OS rate, vinorelbine and cisplatin (NP) for 3-year OS rate, cyclophosphamide, cisplatin, and 5-fluorouracil for 5-year OS rate, NP for complete remission rate, cisplatin and gemcitabine for overall remission rate of the primary tumor. In addition, for certain grade 3 and above toxicity, the results of the NMA reflected certain NCT regimens can reduce toxicity of chemoradiotherapy (CRT) to a minimum, such as NP for anemia, mucositis, and thrombocytopenia, paclitaxel, epirubicin, and cisplatin for neutropenia and skin toxicity.Conclusion:Our NMA showed that certain cisplatin-based NCT regimens improved the prognosis of patients with NPC and reduced the toxicity of CRT. However, in view of survival rate and response rate, the best NCT regimen is not entirely consistent. Therefore, which NCT regimen will benefit most patients will need further explored.

show abstract

OP0005 Neoadjuvant chemotherapy plus chemoradiation (NACT-CCRT) versus chemoradiation plus adjuvant chemotherapy (CCRT-ACT) for locally advanced nasopharyngeal cancer: 3-Year results from a randomised trial

Cited by 3 publications

References 0 publications

Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients

Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?

Contact Info

Product

Resources

About